Clinical Trial: CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07585760) titled 'CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment' on April 13.

Brief Summary: This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by severe renal impairment ([eGFR] < 30 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM) Multiple Myeloma Light C...